Inclusion Criteria:

- adult female patients at least 18 years of age

- able to fully understand and participate in the informed consent process

- history of locally advanced unresectable and/or metastatic breast cancer with
pathology confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC)

- Scheduled to receive either paclitaxel 80 mg/m2 3 weeks on followed by 1 week off or
weekly with treatment breaks as per physician's discretion

- Have no evidence of alopecia with a full set of hair

Exclusion Criteria:

- Patients receiving calcium-lowering therapy or drugs that may affect calcium levels
(e.g., calcitonin, mithramycin, phosphate) within 4 weeks of initiation of topical
calcitriol. Patients who have been managed with bisphosphonates for 6 months or
greater prior to the start of the trial and have demonstrated evidence for stability
of calcium metabolism would be considered eligible for participation in the trial.

- Has a history of drug or alcohol abuse within 1 year of study enrollment as
determined by the investigator.

- Patients who elect to shave the scalp hair prior to the initiation of chemotherapy or
who plan to do so during the chemotherapy treatment.

- Any dermatological condition that in the opinion of the investigator will affect the
absorption of the study medication, e.g. Atopic Dermatitis, etc.

- Has participated in any investigational trial within 30 days or six half-lives of its
biologic activity whichever is longer, before the start of study.

- Patients with a history of hypercalcemia or vitamin D toxicity, or hospitalization
for treatment of angina, myocardial infarction, or congestive heart failure or
psychiatric illness currently or within 30 days of study entry as determined by the
investigator.

- Has a history of significant allergies (including asthma, food or drug allergies) as
determined by the investigator.

- Has any condition that interferes with the ability of the subject to understand or
comply with the requirements of the study.

- Has serum calcium more than ULN (for patients with an albumin lower than 3.0, a
corrected calcium serum calcium = serum calcium +[0.8][3.5- serum albumin]).

- Has been on >400 IU Vitamin D supplements within one week prior to the start of the
study.

- Patients treated with medications that are known to affect calcium levels within 4
weeks of initiation of topical therapy (>500 IU vitamin A, calcium supplements,
fluoride, antiepileptics).

- Patients receiving thiazides or furosemide diuretics

- Patients with hypercalcemia or kidney stones

- Patients that indicate they have significant hair breakage or hair damage and
associated hair loss from hair overprocessing within the last 30 days due to peroxide
applications, permanent hair coloring, bleaches, streaking, perms, relaxers and/or
hair oxidative dyes.

- Any visible signs of androgenic alopecia or alopecia areata or significant hair loss,
hair thinning, or hair breakage.

- Prior radiation to the cranium

- Pregnancy